Project Grant R35GM163726
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $2.5 million Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 1, 2025, with a completion date of August 31, 2029. The award funds research to develop covalent inhibitors of disease-causing proteins and bacterial ribosomes through a novel "fragmentation-first experimentation"...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $462,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective February 10, 2026, with a completion date of January 31, 2031. The award supports fundamental research to elucidate the molecular mechanisms underlying rapid multivesicular body (MVB) formation during synaptic vesicle recycling. The...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $678,370 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), with an award date of May 1, 2026 and completion date of February 28, 2031. The project, titled "Imaging Protein Synthesis on the Ribosome Using Single-Molecule FRET," supports fundamental basic research investigating the kinetic and...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $508,750 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 13, 2026, with a completion date of January 31, 2028. The award supports research and development of a novel methodology for engineering high-fidelity regulatory T cells (Tregs) through integration of CRISPR/Cas9 genome editing...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $768,713 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2030. This award supports fundamental research to advance understanding of epigenetic mechanisms controlling neuroblastoma cell state plasticity and treatment resistance. The project specifically investigates the role of histone...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $647,502 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026, through June 30, 2031. The award funds research to develop small molecule inhibitors targeting DDX19A, an RNA helicase identified as a critical genomic dependency in Ewing sarcoma, an aggressive pediatric bone malignancy. The research applies state-of-the-art...
- Federal Grant Award Summary Purdue University received a $501,917 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2030. This award supports fundamental research into the molecular mechanisms of CRISPR-associated transposons (CASTs) and RNA-guided transcriptional regulation systems. The research leverages single-particle cryo-electron...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $140,809 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 10, 2026, with completion targeted for March 31, 2028. The grant supports comparative vertebrate research investigating neural crest cell (NCC) contributions to hematopoietic stem cell (HSC) specification. The research examines how neural crest cells...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $143,814 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2026, through August 31, 2028. This award supports investigator-initiated research focused on "Reprogramming Chemoresistant Cell States in High-Risk Neuroblastoma," addressing the critical clinical challenge of drug resistance in pediatric cancer...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $151,040 project grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded January 12, 2026, with completion targeted for July 31, 2028. This grant supports research investigating the role of an essential transcription factor in SWI/SNF (Switch/Sucrose Non-Fermentable)-mutant rhabdoid tumors, a lethal childhood cancer driven by inactivation of the SMARCB1...
St. Jude Children's Research Hospital Inc. received a $314,500 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to develop next-generation genome-editing tools based on CRISPR-associated transposons (CASTs). The award, effective July 1, 2026, through June 30, 2031, supports fundamental research to transform CASTs into a versatile and efficient platform for programmable genome integration, particularly for applications in human cells and challenging therapeutic contexts. The project will combine structural biology, high-throughput screening, and machine-learning-based protein design to re-engineer CAST components for enhanced activity, specificity, and cross-species functionality. The research deliverables will address key technical challenges in genome editing by expanding the targeting range of CAST systems, simplifying their molecular composition, and reducing dependence on host factors. Through this five-year initiative, the project aims to create advanced genome-editing tools suitable for safe, precise, and programmable gene insertion in therapeutic and synthetic biology applications. The work builds upon the investigator's prior mechanistic discoveries regarding allosteric regulation of transposase activity and host-factor involvement in integration complex stabilization, positioning the outcomes to significantly advance the field of translational biotechnology and gene therapy development.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $314.5k | 6/11/26 |